QED Therapeutics
Elizabeth Freas has a diverse work experience in the field of clinical research. Elizabeth currently works at QED Therapeutics, where they started in 2020. At QED Therapeutics, they have held two roles: Clinical Program Manager since January 2022 and Senior Clinical Trial Manager from September 2020 to July 2022.
Prior to joining QED Therapeutics, Elizabeth worked at Blue Clinical Research Consulting as an Independent Business Owner/Clinical Operations Consultant from October 2019 to September 2020. Before that, they were a Project Manager at PRA Health Sciences from October 2018 to 2019.
Elizabeth's career in clinical research began at the University of Colorado Denver in 2007. Elizabeth held multiple roles during their time at the university, including Phase I Sponsor Affairs Manager and Project Manager of UM1 Grant from November 2012 to October 2018, Clinical Research Coordinator Supervisor from May 2011 to November 2012, and Clinical Research Coordinator from November 2007 to May 2011.
Overall, Elizabeth has gained extensive experience in clinical research through their various roles in both industry and academic settings.
Elizabeth Freas completed their Bachelor's degree in Mechanical Engineering from Colorado State University from 1999 to 2004.
This person is not in any offices
QED Therapeutics
QED Therapeutics, a subsidiary of BridgeBio Pharma, is a biotechnology company focused on precision medicine for FGFR-driven disorders. QED is also evaluating infigratinib in preclinical studies for the treatment of achondroplasia. They plan to develop infigratinib in additional FGFR-driven tumor types and rare disorders.